CClinicalTrials.gg
CompletedNCT05041231Updated Jan 23, 2023

Effects of Using Custom Photobiomodulation Therapy for the Treatment of Osteoarthritis of the Fingers and Rhizarthrosis

An interventional study of Photobiomodulation therapy (PBT) and Sham Photobiomodulation therapy (Sham PBT) in Osteoarthritis, Osteoarthritis Finger and Osteoarthritis Hand, sponsored by Vita Care. Completed at 1 site in Brazil. Open to participants aged 40 Years to 100 Years. Per ClinicalTrials.gov, last updated 2023-01-23.

Sponsored by Vita Care · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
46
Allocation
Randomized
Ages
40 Years to 100 Years
Sex
All
01

Study summary

Osteoarthrosis (OA), a multifactorial degenerative process, is responsible for joint pain and functional limitation. In the hand, more specifically in the proximal and distal interphalangeal joints of the fingers, it is one of the sites of greatest manifestation of the disease. Numerous treatments, whether drug, rehabilitation or surgery, have been proposed with the aim of both interrupting the natural evolution of the disease and alleviating or stopping the symptoms. This study aims to evaluate the effectiveness of personalized Photobiomodulation Therapy (PBT) with regard to alleviating symptoms and improving the quality of life of these patients with the disease.

02

Conditions studied

  • Osteoarthritis
  • Osteoarthritis Finger
  • Osteoarthritis Hand
  • Osteoarthritis Both Hands

Browse trials for

03

In context

Osteoarthritis

4,398 studies on the registry are indexed under Osteoarthritis; 582 are open to participants now.

This study's enrollment of 46 is below the median of 70 across 3,440 interventional studies indexed under Osteoarthritis.

Browse Osteoarthritis studies →

Lead sponsor

Vita Care is the lead sponsor of 4 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
40 Years to 100 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Clinical and radiological diagnosis of OA of the fingers of the hand and Rizarthrosis
  • Patients with pain for at least 3 months
  • Patients undergoing treatment and rehabilitation for finger OA and rhizarthrosis
  • Patient with good understanding of the Portuguese language who agrees to participate and sign the ICF

Exclusion criteria

Exclusion Criteria:

  • Posttraumatic arthritic changes
  • Systemic inflammatory arthritis (Rheumatoid Arthritis, Lupus Erythematosus, Psoriasis...)
  • Patients with local or systemic, acute or chronic infections
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Outcomes assessor)
Enrollment
46 participants (actual)

Study arms

  • Sham comparator
    Sham (group A)

    Treatment procedure performed with the device that will not provide the bioactive light (laser)

    Device: Sham Photobiomodulation therapy (Sham PBT)

  • Experimental
    PBT (group B)

    Treatment procedure performed with the device that will provide the bioactive light (laser)

    Device: Photobiomodulation therapy (PBT)

Interventions

  • DevicePhotobiomodulation therapy (PBT)

    Any invasive procedures will be done. The treatment in question will be done by a device that looks like a bracelet, which is placed on the hand/fingers to emit light/laser and does not cause pain or temperature change. There will be 8 photobiomodulation sessions, 2 per week, 10 minutes each session. The dosimetric parameters of the therapy will be carried out in a standardized and personalized way, with programming of the light and all the necessary information so that the device can carry out the application of the treatment application of electromagnetic waves in the red and infrared spectral range 660-1000 nm).

    Also known as: Laser

  • DeviceSham Photobiomodulation therapy (Sham PBT)

    Similar to active PBT, however, the device will not provide the active electromagnetic waves)

    Also known as: Sham Laser

06

What researchers measure

Primary outcomes

  1. Change from Baseline Pain at

    Visual analogue scale for pain

    Time frame: 4 weeks and 2 months

  2. Change from Baseline Arm, Shoulder and Hand Disability

    The Disabilities of the Arm, Shoulder and Hand Score

    Time frame: 4 weeks and 2 months

Secondary outcomes

  1. Change from Baseline Hand grip

    Hand grip strenght measured by Digital Hand Dynamometer

    Time frame: 4 weeks and 2 months

  2. Change from Baseline Pinch force

    Pulp to pulp (pinch) force

    Time frame: 4 weeks and 2 months

  3. Willingness to recommend the treatment

    Net Promoter Score

    Time frame: 4 weeks and 2 months

  4. Change from Baseline Hand Disability

    Brief Michigan questionnaire

    Time frame: 4 weeks and 2 months

07

Study locations

1 site
  • Instituto Vita
    São Paulo, SP 05653-070, Brazil
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jan 23, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05041231
Lead sponsor
Vita Care
Collaborators
Tegos S.A.
Responsible party
Sponsor
First posted
Sep 10, 2021
Start date
Aug 25, 2021
Primary completion
Dec 31, 2022
Completion
Jan 20, 2023
Last update
Jan 23, 2023

Study contacts

Mateus Saito, PhD
principal investigator · Medical Director Instituto Vita

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion